22results about How to "Reduce pathological damage" patented technology

The application discloses application of ginsenoside Rb1 in preparation of biological products for improving liver aging and abnormal lipid metabolism. The application research finds that ginsenoside Rb1 (20 mg / kg) can significantly improve the aging phenotype and lipid metabolism disorder of the aging liver through multi-target synergistic effect, and the mechanism is related to inhibition of lipid synthesis, improvement of lipid transport and promotion of lipid oxidation. The application provides a new drug candidate and action mechanism for intervention of aging-related liver diseases such as MASLD / MASH, and has an important clinical application prospect.

The invention discloses a Ruditapes philippinarum miR-263b inhibitor and application thereof, and finds that Ruditapes philippinarum miR-263b can regulate and control innate immune response of a host by targeting RpSC2, negatively regulates activation of an immune-related signal channel in a vibrio infection process, and further, on the basis of a molecular regulation and control mechanism, the Ruditapes philippinarum miR-263b inhibitor can be used for inhibiting the infection of vibrio. The invention discloses a specific inhibitor which is completely complementary with a miR-263b mature body sequence. Experimental data show that after Ruditapes philippinarum is injected with the miR-263b inhibitor, the expression level of miR-263b in vivo is reduced, and the inhibition effect of miR-263b on RpSC2 is effectively relieved, so that the expression level of a target gene RpSC2 is up-regulated, an NF-kappa B immune signal channel is activated, the immune defense capability of the Ruditapes philippinarum on vibrio anguillarum is enhanced, the death rate after infection is remarkably reduced, and the Ruditapes philippinarum is prevented from being infected. The in-vivo bacterium loading amount is obviously reduced, and the pathological injury of hepatopancreas tissue is obviously relieved.

This invention relates to the field of traditional Chinese medicine technology, and more particularly to the application of a traditional Chinese medicine composition in the preparation of drugs for the prevention and treatment of lung injury. The traditional Chinese medicine composition includes Astragalus membranaceus, Eupolyphaga sinensis, Morus alba root bark, Fritillaria cirrhosa, Perilla frutescens seed, Lepidium apetalum seed, Prunus armeniaca seed, Pheretima aspergillum, Ephedra sinica, and Clematis chinensis. Experiments show that this traditional Chinese medicine composition can significantly reduce the level of the inflammatory factor TNF-α, decrease the lung index, and alleviate pathological damage to lung tissue, and can be used for the prevention and treatment of lung injury.

This application discloses the use of itaconic acid derivatives in the preparation of drugs for treating candidemia, belonging to the field of biomedical technology. The itaconic acid derivatives proposed in this application are dimethyl itaconic acid and / or 4-octyl itaconic acid. Dimethyl itaconic acid exhibits a dose-dependent therapeutic effect in model mice, with an optimal dose of 1200 mg / kg improving survival rate and reducing kidney damage; 4-octyl itaconic acid can enhance the anti-Candida albicans ability of macrophages and regulate the expression of inflammatory factors. The application of the itaconic acid derivatives proposed in this application in the treatment of candidemia works through immunomodulation, circumventing fungal resistance. Furthermore, the drugs are low in toxicity, have good biocompatibility, and use a universal experimental system, providing a new approach for the clinical treatment of candidemia with broad application prospects. This application also protects pharmaceutical compositions for treating candidemia with dimethyl itaconic acid and / or 4-octyl itaconic acid as active ingredients.

The invention discloses bifidobacterium longum CCFM1509 with autophagy promoting and colon aging resisting functions and application of the bifidobacterium longum CCFM1509, and belongs to the field of microorganisms. The bifidobacterium longum CCFM1509 provided by the invention can relieve colon tissue pathological damage caused by senescence, reduce the level of proinflammatory cytokines in colon tissues, reduce the oxidative stress level in the colon tissues, reduce the level of senescence-related senescence markers in the colon tissues and adjust the autophagy level in the colon tissues. Therefore, the bifidobacterium longum CCFM1509 disclosed by the invention can be widely applied to the field of medicines and is used for preparing pharmaceutical preparations for preventing or treating colon aging and related diseases; meanwhile, the bacillus subtilis can also be used for developing various functional fermented foods, health foods and formula foods for special medical purposes, provides a new microbial solution for promoting intestinal health and delaying colon senescence, and has important development value and wide market prospects.

The invention discloses an application of a Yinxiaonaotong soft capsule in preparation of a medicine for preventing and treating acute lung injury, and experimental research shows that the Yinxiaonaotong soft capsule can significantly improve lung histopathologic injury of an acute lung injury mouse model activated and induced by a complement bypass and relieve inflammatory cell infiltration. The mechanism of action is as follows: the Yindanaotong can effectively inhibit the expression of key inflammatory mediators (TNF-alpha, IL-6) and adhesion molecules (ICAM-1, P-selectin) in lung tissues and serum. Meanwhile, the medicine can down-regulate the mRNA transcriptional level of NF-kappa B p65, JNK, p38 MAPK and STAT3 signal channel related genes in lung tissues and inhibit phosphorylation activation of corresponding proteins. The results comprehensively show that the Yindan Xinnaotong compound intervenes in an inflammation signal channel through multiple targets, and plays roles in resisting inflammation and protecting lung tissues, so that the Yindan Xinnaotong compound can be used for preparing medicines for preventing and / or treating acute lung injury.

The invention discloses an application of a small molecule drug ATWLPPR Peptide TFA in resisting mycobacterium bovis infection, and belongs to the field of biological medicine, the small molecule drug ATWLPPR Peptide TFA is an agonist of a target host factor NRP1, and then the inhibition effect of the ATWLPPR Peptide TFA on mycobacterium bovis in vitro and in vivo is researched. An in-vitro bacterial loading titration result shows that the ATWLPPR Peptide TFA treatment can present dose-dependent inhibition of the mycobacterium bovis to adhere to A549 cells. Mouse experiment results show that ATWLPPR Peptide TFA treatment can inhibit mice from being infected with mycobacterium bovis, pathological injuries of mouse lung tissues are effectively relieved, and a brand new direction is provided for prevention and control of mycobacterium bovis.

This invention relates to mitochondrial-enriched extracellular vesicles, their preparation methods, and applications, which can effectively solve the drug problem in spontaneous intracerebral hemorrhage. The technical solution involves using platelets as raw material, and obtaining platelet-derived extracellular vesicles carrying active mitochondria through activation induction, differential centrifugation and fractionation, membrane filtration and elution enrichment. This achieves efficient and stable loading of functional mitochondria, and the resulting PEV Mito has a complete structure and uniform particle size, which can effectively maintain mitochondrial membrane potential and biological activity. It can achieve efficient delivery and intracellular internalization to damaged neurons and restore mitochondrial function. The PEV Mito prepared by this invention has high delivery efficiency and excellent biocompatibility, and can be used to prepare drugs for the treatment of intracerebral hemorrhage and secondary neurological injury, with good prospects for clinical translation.

The application provides application of tanshinone or a derivative thereof in preparation of a monkeypox virus resisting drug. In a cell model infected by the monkeypox virus, production of infectious virus particles can be significantly reduced. In a mouse infection model, Tanshinone VII can effectively reduce pathological damage of lung tissues and improve survival rate of animals. The above evidence indicates that Tanshinone VII has potential efficacy in resisting the monkeypox virus. It is inferred that tanshinone or the derivative thereof can play a double role in resisting the monkeypox virus and host protection.

The invention belongs to the technical field of traditional Chinese medicines, and particularly provides a traditional Chinese medicine composition for treating hepatic fibrosis and a preparation method thereof. According to the invention, astragalus membranaceus, vinegar-processed curcuma zedoary, salvia miltiorrhiza, moutan bark, radix paeoniae rubra, angelica sinensis, curcuma aromatica, fructus amomi, bran-fried atractylodes macrocephala koidz, poria cocos, fingered citron, vinegar-processed bupleurum chinense and honey-fried licorice root are adopted as raw materials and are subjected to proper weight proportioning; wherein the astragalus membranaceus is a monarch drug, and the vinegar curcuma zedoary, the salvia miltiorrhiza, the moutan bark, the red paeony root, the angelica sinensis, the radix curcumae, the fructus amomi and the bran-fried rhizoma atractylodis macrocephalae are The vinegar bupleurum chinense, fingered citron and poria cocos are used as adjuvant drugs, and the liquorice is used as conductant drug; all the medicines are combined to achieve the effects of replenishing qi to invigorate the spleen, soothing the liver, regulating qi and promoting blood circulation to remove blood stasis. Under the synergistic effect of all the medicine components, the traditional Chinese medicine composition has a good curative effect on liver fibrosis, especially liver fibrosis common clinically with liver depression, spleen deficiency and blood stasis syndromes, and is small in toxic and side effect and worthy of clinical application and popularization.

This invention discloses the application of the small molecule compound Z2114502286 in the preparation of drugs for the prevention and treatment of liver-related diseases. This invention reveals for the first time that Z2114502286 is a THBS2-specific small molecule inhibitor and verifies its feasibility in preventing and treating liver fibrosis by targeting and inhibiting the THBS2 protein. Through virtual screening and molecular docking, this compound can directly bind to the THBS2 protein. In vitro and in vivo studies show that this compound inhibits THBS2-mediated HSC activation in a concentration- and time-dependent manner, inhibits ECM deposition in a mouse model of liver fibrosis, downregulates the expression of fibrosis-related genes, and alleviates liver inflammation and macrophage infiltration. Simultaneously, the targeted efficacy was verified in a transgenic mouse model specifically expressing human THBS2, demonstrating significant clinical translational value. Furthermore, it exhibits bioavailability and safety at effective dosages, showing broad clinical application prospects.

This invention provides the application of a uterine-derived Sphingomonas DS-28 strain and its metabolites in the treatment of endometritis, relating to the field of microbial technology. The Sphingomonas DS-28 strain provided by this invention possesses uterine colonization ability, good niche adaptability, and significant efficacy in treating Escherichia coli-induced endometritis. Animal experiments show that the preparation of this strain can effectively alleviate uterine redness and swelling, reduce pathological damage, and significantly reduce [the condition / progression]. TNF-alpha , IL-6 , IL-8 It inhibits gene expression and suppresses the NF-κB signaling pathway, exhibiting superior anti-inflammatory and tissue repair effects compared to other Sphingomonas strains C3-25.1, C3-41.1, and C3-42.1. Furthermore, the metabiotic preparation of this strain can also alleviate Escherichia coli-induced endometritis in mice, improve uterine redness and swelling, and reduce pathological damage.

The application provides an application of exemestane or a derivative thereof in preparation of a medicine for protecting against radiation-induced intestinal injury, and further provides a medicine composition for protecting against radiation-induced intestinal injury, which is composed of exemestane or a derivative thereof and pharmaceutically acceptable adjuvants. The application first screens and locks the exemestane from a high-throughput screening of 3067 compounds approved by FDA. Through a mouse model of radiation-induced intestinal injury, it is verified that the survival rate of mice can be significantly improved by intragastrically treating the mice with 6.25 mg / kg of exemestane 2 hours before whole body 8 Gy irradiation. HE histology shows that the intestinal crypt-villus structure integrity of the mice in the exemestane administration group is recovered, the bone marrow cavity emptiness degree is reduced, and the spleen injury is reduced. The above results prove that the exemestane can protect the intestine, hematopoietic and immune organs at the whole animal level, and is a rare small molecule compound for protecting multiple organs. The application provides a new basis for exemestane or a derivative thereof for protecting against radiation-induced intestinal injury.

The application belongs to the technical field of biological medicine, and specifically discloses a kind of hybrid peptide B5PL and its application in preparation of anti-infection drugs.The amino acid sequence of the hybrid peptide B5PL is shown as SEQ ID NO.1, and research proves that the hybrid peptide B5PL can destroy bacterial cell membranes, regulate immune homeostasis, and thus play a role in preventing and treating drug-resistant Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli, Streptococcus suis and Actinobacillus pleuropneumoniae infections.In a mouse peritoneal infection MRSA model, B5PL can significantly reduce lung pathological damage caused by infection, specifically manifested as improved alveolar structure integrity, reduced inflammatory cell infiltration, and significantly improved mouse survival rate, showing good anti-infection treatment potential.The hybrid peptide B5PL provided by the application is expected to become an antibiotic replacement drug, and has good application prospect.

The invention discloses application of berbamine in preparation of a ferroptosis inhibitor and / or a drug for preventing and treating drug-induced liver injury, the ferroptosis inhibitor is a hepatocyte ferroptosis inhibitor, and the drug is a drug for drug-induced liver injury induced by acetaminophen. The invention also provides application of berbamine in preparation of a liver enzyme inhibitor, an APAP-induced liver tissue oxidative stress inhibitor, a ferroptosis signaling pathway protein expression promoter and a liver tissue ferroptosis marker PTGS2 expression inhibitor. The application has the advantages that the fact that berbamine can inhibit hepatocyte ferroptosis by regulating an NRF2 / GCLC / GPX4 antioxidant axis and an FSP1 pathway is revealed for the first time, so that a new treatment strategy is provided for ferroptosis related diseases and drug-induced liver injury.

This invention discloses a porcine reproductive and respiratory syndrome virus (PRRSV) mRNA molecule and its applications. Four mRNA vaccines, GP35m-LNP, GP45m-LNP, GP345m-LNP, and GP2345m-LNP, were designed by combining the NADC30-like structural proteins GP2a, GP3, GP4, and GP5 of the PRRSV FJ1402 strain. Mouse experiments showed that GP345m-LNP induced both strong humoral and cellular immune responses, followed by GP2345m-LNP, with better efficacy than the inactivated vaccine (which only induced humoral immunity). After immunization, challenge with the PRRSV FJ1402 strain resulted in significantly reduced viral load in the blood and lungs of the GP345m-LNP group, with significantly less pathological damage to the lungs. The immunization effect was superior to the inactivated vaccine group, demonstrating promising application prospects.

The invention discloses an application of Harman alkali in the aspect of preparing a Pseudomonas plecoglossicida inhibitor, and is characterized in that the Harman alkali is applied in the aspect of preparing a medicine for preventing and / or treating aquatic animal infectious diseases caused by Pseudomonas plecoglossicida. The invention further provides application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating aquatic animal plecoglossus altivelis pseudomonas infection, application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating plecoglossus altivelis liver injury, application of a plecoglossus altivelis immunoregulation medicine and application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of an aquaculture feed additive. The method has the advantages that the survival rate of aquatic animals can be remarkably increased in a Pseudomonas plecoglossicida infection model, the bacterial load in immune tissues such as blood, liver, spleen, head and kidney and the like is reduced, and liver and spleen tissue pathological injury and cell apoptosis caused by infection are relieved; meanwhile, harmine can improve biochemical and antioxidant indexes of infection-related serum, and has no obvious toxicity to fish-derived cells within a certain concentration range.

The application discloses ganoderma lucidum polysaccharide GLFP2, a preparation method thereof and application of the ganoderma lucidum polysaccharide GLFP2 in treating mycoplasma pneumoniae pneumonia, and belongs to the medical field. The monosaccharide composition of the ganoderma lucidum polysaccharide GLFP2 is mannose, glucuronic acid, glucose, galactose and fucose, and the molar ratio is 2.19:7.89:54.53:6.29:1.3; the glycosidic bond type thereof includes 1,4-connected beta-glucose, 1,3,6-connected alpha-mannose, 1,3-connected beta-glucuronic acid, and has beta-1,6-galactose side chains. The ganoderma lucidum polysaccharide GLFP2 provided by the application has a clear structure and high purity. Experiments prove that in a mycoplasma pneumoniae infected mouse model, the ganoderma lucidum polysaccharide GLFP2 can significantly reduce lung tissue inflammatory cell infiltration and pathological damage, and effectively reduce lung tissue mycoplasma load. Therefore, the GLFP2 can be used as an effective candidate component for developing a new type of anti-mycoplasma pneumonia drug.

The application belongs to the field of clinical drug toxic side effects, and particularly relates to the use of phenazine-1-carboxylic acid in treating cisplatin-mediated acute kidney injury. The application first discovers and proves that phenazine-1-carboxylic acid can effectively alleviate cisplatin-induced acute kidney injury. In a cisplatin-induced acute kidney injury model of mice, intraperitoneal injection of phenazine-1-carboxylic acid can effectively protect kidney function, which is specifically manifested as follows: significantly reducing urea nitrogen and creatinine levels in serum of model mice; reducing pathological injury of kidney tissue and reducing tubular injury score; and inhibiting expression of inflammatory factors and injury markers in kidney tissue. The treatment effect is equivalent to that of a classic ferroptosis inhibitor, Ferrostatin-1, and a new candidate drug for solving the dose-limiting toxicity of cisplatin in clinical application is provided.

The invention provides application of bisdemethoxycurcumin in preparation of a medicine for preventing and / or treating radiation brain injury, raw material medicines of the bisdemethoxycurcumin are prepared by taking microcrystalline cellulose, hydroxypropyl cellulose, sodium carboxymethyl starch and bisdemethoxycurcumin as raw materials, then a diluent is added, and finally a lubricant is added, so that the bisdemethoxycurcumin is prepared. The bisdemethoxycurcumin dispersible tablet is prepared by the following steps of: uniformly mixing the raw materials, and directly tabletting by using a single-punch tablet press, so that the bisdemethoxycurcumin dispersible tablet can reduce the encephaledema rate, the SOD (superoxide dismutase) content and brain pathological injury after radiotherapy.

The application discloses lactobacillus plantarum WH021 and application thereof in prevention and / or alleviation of neuroinflammation, and belongs to the technical field of microorganisms. The lactobacillus plantarum WH021 is obtained by separation and purification from healthy infant feces, is a probiotic with the effect of alleviating neuroinflammation, and has good application potential in development of food, health products and drugs for preventing brain inflammation related diseases of middle-aged and old people caused by chronic inflammation of the body.

This invention provides the application of ZBP1 or its encoded protein in the preparation of products for diagnosing septic cardiomyopathy, relating to the field of biomedical technology. Transcriptome sequencing analysis of a septic cardiomyopathy model revealed the activation of multiple programmed cell death-related pathways. Further screening using the intersection of differentially expressed genes and pan-apoptotic gene sets identified ZBP1, which showed an upregulated trend in the model. Validation was achieved through an in vivo cardiomyocyte-specific ZBP1 gene knockout model and in vitro cardiomyocyte knockdown experiments. Results showed that regulating ZBP1 expression can affect the expression of multiple programmed cell death-related molecules and is associated with myocardial injury and inflammatory responses. This invention suggests that ZBP1 may participate in the pan-apoptotic process and provides a novel potential molecular target for septic cardiomyopathy.